No patient left behind: The promise of immune priming with epigenetic agents

Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually b...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Oronsky, Bryan T., Roswarski, Joseph, Oronsky, Arnold L., Oronsky, Neil, Scicinski, Jan, Lybeck, Harry, Kim, Michelle M., Lybeck, Michelle, Reid, Tony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665084/
https://www.ncbi.nlm.nih.gov/pubmed/29123948
http://dx.doi.org/10.1080/2162402X.2017.1315486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665084/
https://www.ncbi.nlm.nih.gov/pubmed/29123948
http://dx.doi.org/10.1080/2162402X.2017.1315486

Ejemplares similares